you seemed to hit all the "counterpoints" to the FUD that has been spread ad nauseum for months now (dare I say years)
No other time in this company's history matches this critical juncture.. I would mirror Karen's post (earlier) stating that I would be concerned if some kind of partnership did not materialize before the end of 2018.. (but I am expecting one much sooner:)
IPIX management has done an excellent job to this point setting the table for success (are they perfect.. no).. but if I were grading on a curve.. IPIX would get a SOLID A.
stock price.. the timing of trial data.. reprioritizing targets.. it is easy to take the eye off the ball..
this is a small cap biotech that has kept its focus on what matters.. good trial data..
Market Data 
Markets 
AI
